Healthcare / Drug Manufacturers - Specialty & GenericStuttgart
$0.41
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $3.4B · quality 76.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
59/100
C
Piotroski
8/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$285M
P/E
4.1x
↓EV/EBITDA
0.5x
↓ROE
12.2%
↑Gross Margin
44.2%
↓Debt/Equity
0.13
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
+14.6%
FCF CAGR
+20.9%
FCF margin
13.8%
FCF / Net income
1.05x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $44.39B · net income $5.83B · FCF $6.13B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $44.39B | $44.39B | $39.27B | $34.67B | $29.49B |
| Net Income | $5.83B | $5.83B | $4.61B | $5.12B | $5.13B |
| EBITDA | $10.64B | $10.64B | $9.37B | $9.28B | $7.39B |
| EPS | 13.07 | 13.07 | 10.34 | 11.48 | 11.49 |
| Gross Margin | 44.2% | 44.2% | 44.1% | 45.6% | 47.2% |
| Operating Margin | 19.3% | 19.3% | 18.3% | 19.7% | 22.6% |
| Net Margin | 13.1% | 13.1% | 11.8% | 14.8% | 17.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.13 | 0.13 | 0.24 | 0.30 | 0.21 |
| Current Ratio | 2.13 | 2.13 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $6.13B | $6.13B | $3.37B | $2.27B | $3.46B |
| Returns | |||||
| ROE | 12.2% | 12.2% | 10.6% | 12.6% | 13.8% |
| Valuation | |||||
| P/E | 4.10 | 4.10 | 0.04 | 0.07 | 0.08 |
| EV/EBITDA | 0.50 | 0.50 | 1.03 | 1.25 | 1.00 |
| P/B | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 |
| Growth & Yield | |||||
| Revenue Growth | 13.1% | 13.1% | 13.3% | 17.5% | — |
| EPS Growth | 26.4% | 26.4% | -9.9% | -0.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-85.9%
EPS terminal req.
$0.04
Spread vs growth
112.3%
5Y implied EPS CAGR
-68.0%
EPS terminal req.
$0.04
Spread vs growth
94.4%
10Y implied EPS CAGR
-40.6%
EPS terminal req.
$0.07
Spread vs growth
67.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-4.7%
Start / end P/E
0.0x → 0.0x
EPS bridge
10.34 → 13.07
Residual
-6.5%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.